Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes

Xenobiotica

Volumn 29, Issue 3, 1999, Pages 217-229

  Shiraga, T ^a   Kaneko, H ^a   Iwasaki, K ^a   Tozuka, Z ^a   Suzuki, A ^a   Hata, T ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; FURAFYLLINE; HYDROLASE; NEUROLEPTIC AGENT; RECOMBINANT PROTEIN; SULFAPHENAZOLE; UNSPECIFIC MONOOXYGENASE; ZOTEPINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; OXIDATION; RAT;

ANIMALIA;

EID: 0033066470     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238623     Document Type: Article

References (29)

1. AKAIKE, H., 1974, A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716-723.
2. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131-137.
3. BACK, D. J., TJIA, J. F., KARBWANG, J. and COLBERT, J., 1988, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology, 26, 23-29.
4. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
5. BARNAS, C., STUPP̈CK, C. H., MILLER, C., HARING, C., SPERNER-UNTERWEGER, B. and FLEISCHHACKER, W. M., 1992, Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. International Clinical Psychopharmacology, 7, 23-27.
6. BERTZ, R. J. and GRANNEMAN, R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210-258.
7. FLEISCHHACKER, W. W., BARNAS, C., STUPPÄCK, C. H., UNTERWEGER, B., MILLER, C. and HINTERHUBER, H., 1989, Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacology Bulletin, 25, 97-100.
8. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEN, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
9. GUENGERICH F. P., KIM, D.-H. and IWASAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
10. HEBERT, M. F., ROBERTS, J. P., PRUEKSARITANONT, T. and BENET, L. Z., 1992, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clinical Pharmacology and Therapeutics, 52, 453-457.
11. HIGASHI, Y., MOMOTANI, Y., SUZUKI, E. and KAKU, T., 1987, Clinical and EEG studies of zotepine, a thiepine neuroleptic, on schizophrenic patients. Pharmacopsychiatrie, 20, 8-11.
12. INOUE, K., YAMAZAKI, H., IMIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
13. KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R. M. and WATKINS, P. B., 1994, CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4, 247-259.
14. LAWTON, M. P., CASHMAN, J. R., CRESTEIL, T., DOLPHIN, C. T., ELFARRA, A. A., HINES, R. N., HODGSON, E., KIMURA, T., OZOLS, J., PHILLIPS, I. R., PHILPOT, R. M., POULSEN, L. L., RETTIE, A. E., SHEPHARD, E. A., WILLIAMS, D. E. and ZIEGLER, D. M., 1994, A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Archives of Biochemistry and Biophysics, 308, 254-257.
15. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R. WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NERBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
16. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
17. NODA, K., SUZUKI, A., OKUI, M., NOGUCHI, H., NISHIURA, M. and NISHIURA, N., 1979, Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man. Arzneimittel-Forschung/Drug Research, 29, 1595-1600.
18. ONO, S., HATANAKA, T., MIYAZAWA, S., TSUTSUI, M., AOYAMA, T., GONZALEZ, F. J. and SATOH, T., 1996, Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica, 26, 1155-1166.
19. OTANI, K., KONDO, T., KANEKO, S., HIRANO, T., MIHARA, K. and FUKUSHIMA, Y, 1992, Steady-state serum kinetics of zotepine. Human Psychopharmacology, 7, 331-336.
20. OTTON, S. V., CREWE, H. K., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242-247.
21. PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALOW, W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Pharmacology, 53, 531-538.
22. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., SEGURA, M. J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651-663.
23. SHIMADA, T., YAMAZAKI, H., MIMURA, M. INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
24. TANAKA, O., 1996, Pharmacokinetics of zotepine and various factors affecting that of zotepine. Japanese Journal of Psychopharmacology, 16, 49-52.
25. THUMMEL, K. E., O'SHEA, D., PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. and WILKINSON, G. R., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics, 59, 491-502.
26. UCHIDA, S., HONDA, F., OTSUKA, M., SATOH, Y., MORI, J., ONO, T. and HITOMI, M., 1979, Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy)dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug. Arzneimittel-Forschung/Drug Research, 29, 1588-1594.
27. WRIGHTON, S. A., BRIAN, W. R., SARI, M.-A., IWASAKI, M., GUENGERICH, F. P., RAUCY, J. L., MOLOWA, D. T. and VANDENBRANDEN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology, 38, 207-213.
28. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. and UNO, T., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879-885.
29. ZIEGLER, D. M., 1988, Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metabolism Reviews, 19, 1-32.